A. Truesdale

发表

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.

P. A. Harris, J. Veal, Rakesh Kumar, 2008, Journal of medicinal chemistry.

Agouti regulation of intracellular calcium: role of melanocortin receptors.

W. Wilkison, M. Zemel, A. Truesdale, 1997, The American journal of physiology.

Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor

R. Bast, B. Champion, F. Schoenen, 1994, Nature.

Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases.

J. D. Stuart, A. Truesdale, Laurie S. Kane-Carson, 2007, Bioorganic & medicinal chemistry letters.

4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors.

A. Truesdale, Y. Maeda, Hideyuki Sato, 2004, Bioorganic & medicinal chemistry letters.

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Krystal J Alligood, Karen Lackey, K. Lackey, 2004, Cancer Research.

Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs.

L. Moore, J. Besterman, A. Truesdale, 1993, Journal of medicinal chemistry.

Agouti antagonism of melanocortin binding and action in the B16F10 murine melanoma cell line.

W. Wilkison, S. Blanchard, A. Truesdale, 1995, Biochemistry.

Discovery of an inhibitor of insulin-like growth factor 1 receptor activation: implications for cellular potency and selectivity over insulin receptor.

E. Alvarez, L. Shewchuk, H. Xie, 2009, Biochemical pharmacology.

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

Ming-Chih Crouthamel, L. Harrington, T. Gilmer, 2007, Molecular Cancer Therapeutics.

Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase.

J. Veal, Liping Wang, R. Nolte, 2005, Bioorganic & medicinal chemistry letters.

Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.

L. Shewchuk, T. Gilmer, A. Truesdale, 2008, Cancer research.

Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.

D. Vanderwall, L. Shewchuk, A. Goetz, 2009, Bioorganic & medicinal chemistry letters.

Mutations in the carboxyl terminus of the agouti protein decrease agouti inhibition of ligand binding to the melanocortin receptors.

W. Wilkison, K. Bunce, A. Truesdale, 1997, Biochemistry.

Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2.

Liping Wang, R. Nolte, A. Truesdale, 2007, Bioorganic & medicinal chemistry letters.